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Abstract 
We assessed comparatively the diagnostic value of two potential malignant pleural 
mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin.  
Material and methods: We measured serum and pleural fluid values of mesothelin and 
hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas 
(Mets group) and 27 patients with benign pleural effusion related to asbestos exposure 
(BPLAE). 
Results: Using a serum HA cut-off of 100 µg/L, 8 patients/33 (24.2 %) were positive in the 
Mets group vs 20 /76 (26.3 %) in the MPM group and only 1 /27 BPLAE patients. The area 
under ROC curve for serum HA in MPM versus Mets or BPLAE groups was only 0.617 
while it was 0.755 for mesothelin. In pleural fluid, both markers had similar diagnostic values.  
Conclusions: Serum mesothelin is more sensitive than hyaluronic acid in diagnosing MPM 
and there is no benefit in combining both markers.  
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Introduction 
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis. Clinical 
symptoms are not specific and most patients are referred and diagnosed late in the course of 
the disease. A reliable histologic diagnosis of malignant pleural mesothelioma requires 
performing multiple pleural biopsies. However many patients are not clinically able to 
undergo thoracoscopy or transthoracic pleural biopsies. Moreover, the histologic diagnosis 
may be also difficult due to the broad range of microscopical features of these pleural tumors 
[1]. Common diagnostic difficulties include differentiation of epithelioid subtype 
mesothelioma from adenocarcinomas and sarcomatoid subtype mesothelioma from 
sarcomatoid carcinoma or sarcoma. Therefore, in patients with malignant pleural effusions 
and a clinical suspicion of MPM, tumor markers would be useful for diagnosis or evaluating 
prognosis and response to treatment [2]. Hyaluronic acid (HA) has been proposed as a 
putative diagnostic marker for mesothelioma but high serum levels have been described only 
in advanced stage mesothelioma [3]. Moreover a significant proportion of mesothelioma do 
not secrete HA [4, 5]. However high pleural levels of HA (higher than 100 mg/L) have been 
considered to be specific for MPM diagnosis. Despite a quite high area under the ROC curve 
(0.752) reported by Fuhrman et al. [6], the sensitivity of the test is only about 40 % to 70% at 
most [7-10]. More recently soluble mesothelin [11-13] emerged as a potential diagnostic 
marker for MPM. To our best knowledge, there are no data concerning the concomitant 
assessment of mesothelin and hyaluronic acid. Historically hyaluronic acid assays relied on 
High Pressure Liquid Chromatography (HPLC) or on radio-immunologic techniques but an 
easier ELISA-like technique which uses a specific hyaluronic acid binding protein (HABP) 
for capture and detection has been described and commercialized [14]. 
We therefore compared the potential diagnostic utility of hyaluronic acid and soluble 
mesothelin in a group of patients with pleural effusion and suspected of MPM. 
Material and methods  
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Patients 
Starting May 2003, we recruited consecutive patients suspected of malignant pleural 
mesothelioma (MPM) from 20 different pulmonary or thoracic surgery departments from the 
North and West of France. All these patients had clinical symptoms consistent with this 
diagnosis, i.e. at least chest pain or dyspnoea associated with pleural thickening and an 
exsudative pleural effusion. In all patients other causes of pleural effusions were excluded and 
a definitive pathological diagnosis was established after multiple pleural biopsies, following 
recent international guidelines [15]. Exclusion criteria were any concomitant infectious 
disease and previous anti-cancer therapy. 
Final diagnosis, based on pleural histology, divided the patients into three groups: 76 patients 
with confirmed MPM, 27 patients with benign pleural lesions associated with asbestos 
exposure (BPLAE group), and 33 patients with pleural metastasis of various carcinomas 
(Mets group). Table I shows the main characteristics of the patients. Some of the patients 
from the present study were also included in our previous report [13] comparing the 
diagnostic value of osteopontin and mesothelin.  
A standard operating procedure concerning patients sampling and data retrieval was set in 
place. Serum, as well as pleural fluid samples retrieved without anticoagulant, if available, 
were collected from each patient and stored at -80°C in aliquots until analyzed. Clinical data 
and outcome of the patients were also collected after informed consent. The local ethics 
committee approved the study protocol. 
Assaying of tumor markers in serum and pleural effusions 
Hyaluronic acid and soluble mesothelin assays were performed using respectively Hyaluronic 
Acid (HA) test kit (Corgenix, Inc, Denver, Colorado, USA) and Mesomark (CisBio 
International, Gif/Yvette, France) kit assays according to the manufacturer instructions. 
Statistical analysis 
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Results were reported as mean and standard deviation (for age) or as median values with the 
corresponding interquartile ranges (IQR) (for all other parameters). Comparisons between 
groups were performed using both Kruskal-Wallis test and a non parametric ANOVA after 
rank transformation as suggested by Conover [16]. The Bonferroni correction was applied for 
multiple comparisons in post hoc tests. All tests were two sided and a p value of 0.05 or less 
was considered significant. Areas under ROC curves (AUC) are reported with their 95% 
confidence intervals (CI) in parenthesis. Comparisons of AUC were done as suggested by 
Hanley using values available for both parameters [17]. Unavailable data was coded as 
missing.  
Results 
Of the 136 patients recruited, 33 (24.3 %) had pleural metastasis of various carcinomas (Mets 
group), 27 (19.9 %) had benign pleural lesions associated with asbestos exposure (BPLAE 
group) and 76 (55.8 %) had a malignant pleural mesothelioma (MPM group). The majority 
(60 cases - 79 %) had an epithelioid mesothelioma. Sarcomatoid and mixed type tumors were 
diagnosed in eight cases (10.5 %) each. Details concerning demographic characteristics are 
given in table I. The mean age was slightly lower in the BPLAE group but the difference was 
not statistically significant (p=0.09). As expected, there was a male gender predominance in 
the BPLAE (100%) and MPM (80%) groups due to the occupational nature of the asbestos 
exposure.  
Serum hyaluronic acid and mesothelin levels 
In serum, a significant difference of HA was observed between patients with mesothelioma 
(median 48.5 µg/L IQR 29.5 - 100.5) and benign cases (median 30.0 µg/L IQR 13.0 – 56.0) 
(p=0.009) but not with those with pleural metastasis of carcinomas (median 45.0 µg/L IQR 
19.0 - 91.0) (p=0.23) (Figure 1 A). The AUC for serum HA in the differential diagnosis of 
MPM versus all other types of pleural involvement was only of 0.617 (95 CI 0.520 – 0.714) 
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while it was 0.672 (95 CI 0.558 – 0.785) for the differential diagnosis of malignant (Mets and 
MPM) and benign pleural lesions (figure 1C and 1D respectively).  
As already reported, serum mesothelin values were much higher in MPM than in both Mets 
and BPLAE patients (Figure 1B). Mesothelin had higher AUC than serum HA for 
differentiating malignant (Mets and MPM) and benign pleural lesions (0.774, 95 CI 0.681 – 
0.867) or MPM versus all other type of pleural involvement (0.755, 95 CI 0.671 – 0.840) 
(figure 1 C and 1D).  
We tried to assess the optimal cut-off values for HA using the Youden index. The maximum 
values of the Youden index were 0.24 when differentiating between patients with MPM and 
other diseases and 0.29 for discriminating malignant and benign pleural involvement. These 
values corresponded to cut-off values for hyaluronic acid of 26.5 µg/L (sensitivity=0.83, 
specificity=0.42) and 14.5 µg/L (sensitivity=0.92, specificity=0.37). These very low 
specificities are of little utility for the diagnostic process. Therefore, we considered a cut-off 
value of 100 µg/L, which resulted in a specificity of 0.85 when differentiating between 
patients with MPM and those with other diseases and of 0.95 when differentiating between 
neoplastic and benign pleural involvement respectively.  
With this new cut-off, we also wanted to know if serum HA could help the diagnosis of MPM 
in patients with low serum values of mesothelin (Figure 2). Among the 36 patients with MPM 
and a serum mesothelin value lower than 1.75 nM, a cut-off that give a specificity of at least 
0.95 (similar to our previous investigations [12, 13]), only 6 (16.6%) patients had a serum HA 
at or above the cutoff of 100 µg/L (with values of 100, 101,129, 148, 153, 330 µg/L: 4 
epithelioid, 1 mixed type and 1 sarcomatoid MPM). In the Mets group four out of 23 patients 
(17.4%) had a low level of serum mesothelin but a high level of serum HA while only one of 
the 26 BPLAE patients was in the same situation. Thus serum HA can “rescue” the diagnosis 
of pleural malignancy in about 15% of the cases but is unable to differentiate between MPM 
and Mets groups.  
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Hyaluronic acid and mesothelin levels in pleural effusions 
Pleural fluid values for HA and mesothelin were available in only 20 patients in the Mets 
group, 13 patients in the BPLAE group and 26 patients in the MPM group. Pleural values for 
pleural HA were grossly 1000 times higher than the corresponding serum values. The median 
values for pleural HA were higher in patients with MPM (133.2 mg/L IQR 20.5 – 336.2) 
compared with the other two groups (11.4 mg/L IQR 8.1 – 22.8 for Mets group and 22.1 mg/L 
IQR 8.5 – 38.4 for BPLAE Group) (Figure 3A). A similar picture was found for pleural 
mesothelin with median values of 20.5 nM (IQR 7.45 - 106.8) for MPM patients, 7.3 nM 
(IQR 2.9 -20.3) for Mets patients and 8.1 nM (IQR 4.0 - 15.3) for BPLAE patients (Figure 
3B). The AUC for the two markers when differentiating between MPM and other type of 
pleural involvement were similar (0.832 for mesothelin and 0.810 for HA respectively)(Figure 
3C). With a cut-off of 50 nM for mesothelin and 50 mg/L for HA, a specificity higher than 95 
% can be obtained with a sensitivity between 50 and 60 %. When we compared the pleural 
levels of mesothelin and HA in the same patients (figure 3D) we found that the two variables 
were highly correlated (Spearman Rho=0.647, p=0.001). There was only one patient with low 
pleural level of mesothelin which had a high pleural HA value. Therefore, the combination of 
the two pleural effusion markers in our series seemed of little interest for the diagnosis of 
MPM.  
Discussion  
Malignant pleural mesothelioma is a severe disease with an increasing incidence in both 
developed and emerging countries. MPM prognosis remains poor despite recent treatments. 
Survival may be improved by an early diagnosis and a multimodal therapeutic approach. 
Unfortunately, the clinical picture is not specific and yet there are no validated tools for 
screening or early diagnosis of MPM. Even in patients with an advanced pleural involvement, 
the diagnosis can be difficult due to the variability of the histologic aspect of mesothelioma 
and the potential development of other pleural diseases in asbestos-exposed subjects (benign 
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lesions, pleural metastases of adenocarcinoma). Therefore, serum diagnostic markers would 
be very useful in clinical practice helping to refer the patients suspected of MPM earlier for 
investigations. Historically hyaluronic acid has been the first proposed marker and recent 
reports [11, 12] suggested that soluble mesothelin can also be useful for this purpose.  
In the present investigation, we showed that serum HA is elevated in patients with MPM but 
this marker had a moderate ability to discriminate between patients with MPM and those with 
other pleural diseases. The lack of specificity of serum HA is due to the elevated values found 
in patients with pleural metastases of various carcinomas. Soluble Mesothelin had a higher 
AUC than HA for MPM diagnosis. However, the most important problem of soluble 
mesothelin remains the less than optimal sensitivity, which was about 40% in this study. The 
best estimates found in the literature are at most 70% if we aim at a specificity of at least 
90%. 
The addition of hyaluronic acid to mesothelin assessment in blood could orientate the 
diagnosis in about 15 % of the cases of MPM which have low mesothelin values. This figure 
can be regarded as low and the real usefulness in practice is debatable in our opinion, since 
most of these patients still had to undergo a thoracoscopy. Interestingly this additional value 
of HA was not restricted to patients with epithelioid subtype of mesothelioma. Blood 
assessment of HA could be eventually used in patients with a high clinical suspicion of MPM, 
but without a histological proof of cancer and no prospect of chemotherapy, and a low serum 
mesothelin value. In a similar way, some authors reported that if diagnosis of mesothelioma is 
based only on a cytological examination the addition of a pleural HA assay can improve 
sensitivity without significantly compromising specificity [18]. The assessment of HA in the 
pleural fluid had a better diagnostic value than in serum. Nevertheless, since HA levels were 
highly correlated with mesothelin levels in pleural effusion, combining the two markers gave 
redundant information and therefore would be of limited usefulness in clinical practice. The 
value of serum HA is further reduced by the fact that the levels of this marker are elevated in 
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case of hepatic fibrosis or inflammatory joint diseases such as rheumatoid arthritis. Therefore, 
we suggest that soluble mesothelin should be the sole marker to be initially investigated. This 
proposal is also sustained by other authors which reported that combining mesothelin with 
other potential markers as CYFRA21.1, osteopontin or CA 125 was also not helpful for 
improving MPM diagnosis [13, 19, 20] 
In conclusion, serum mesothelin had a better diagnostic value than serum hyaluronic acid and 
therefore may be considered as the reference biological marker to which all other candidates 
should be compared in MPM diagnosis. In pleural effusion, both markers were equally 
effective in diagnosing MPM. 
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Table I. Demographic data of the recruited patients 
 
Mets (n=33) BPLAE (n=27) MPM (n=76) 
Age years (mean ± SD) 66.7 ± 10.5 61.4 ± 10.7 66.1 ± 9.7 
Male gender n (%) 22 (66.7 %) 27 (100 %) 61 (80.3 %) 
Diagnosed by 
- Blind Pleural Biopsy 
- Thoracoscopy 
- Surgery (VATS or open surgery) 
- Guided biopsy (CT or US) 
 
- 
24 (72.7 %) 
6 (18.2 %) 
3 (9.1 %) 
 
- 
18 (66.7 %) 
9 (33.3 %) 
- 
 
1 (1.3 %) 
48 (63.1 %) 
25 (33 %) 
2 (2.6 %) 
Confirmed asbestos exposure n (%) 11 (33.3 %) 22 (81.5 %) 63 (82.9 %) 
CT = computed tomography US = Ultrasound; Mets = pleural metastasis of carcinoma; 
BPLAE = benign pleural lesions associated with asbestos exposure; MPM = malignant pleural 
mesothelioma, VATS = Video Assisted Thoracic Surgery 
14 
 
Figure legends 
 
Figure 1 Diagnostic utility of serum hyaluronic acid and mesothelin in patients suspected of 
malignant pleural mesothelioma (MPM). (A) Serum values of hyaluronic acid and (B) serum 
mesothelin; the horizontal bar shows the median and the doted horizontal line in pane A the 
selected cut-off value for Hyaluronic acid (100 µg/L); (C) ROC curve for serum mesothelin 
and hyaluronic acid for differentiating MPM versus all other pleural effusions and (D) 
malignant pleural effusions (MPM and ADK) versus benign pleural lesions associated with 
asbestos exposure (BPLAE) Numbers on the graphs represent cut off values for each marker 
at the respective inflection points. 
 
 
Figure 2. Correlations between serum values of mesothelin and hyaluronic acid in patients 
with MPM (solid squares), pleural metastases of carcinomas (triangles) and benign pleural 
effusions (circles). The Rho values represent the Spearman correlation; the statistically 
significance p is two tailed. 
 
 
Figure 3 Diagnostic value of pleural mesothelin and hyaluronic acid. Pleural levels of (A) 
hyaluronic acid and (B) mesothelin; horizontal lines represent median values for each group. 
(C) ROC curves for mesothelin (solid line) and hyaluronic acid (dotted line) for 
differentiating MPM vs other types of pleural effusions; (D): correlation between pleural 
values of mesothelin (x axis) and hyaluronic acid (y axis) in patients with MPM (solid 
squares), pleural metastases of carcinomas (triangles) and benign pleural effusions (circles). 
The Rho values represent the Spearman correlation; the statistically significance p is two 
tailed 
